Anti TNF ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
96クローン病10

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02872506
(ClinicalTrials.gov)
September 201716/8/2016Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical ResectionComparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical ResectionQuality of LifeDrug: Anti TNF;Procedure: ileocecal resectionUniversity Hospital, LilleNULLWithdrawn18 YearsN/AAll0N/ANULL
2NCT01881464
(ClinicalTrials.gov)
May 201411/6/2013Anti TNF a Improves Endothelial Dysfunction in IBD PatientsAnti TNF a Improves Endothelial Dysfunction in IBD PatientsCrohn's DiseaseDevice: Endopath from Itamar medical - FDA approved device.;Drug: Anti TNF Alfa.Carmel Medical CenterNULLRecruiting18 Years40 YearsBoth20Israel
3JPRN-UMIN000005762
2010/10/2713/06/2011The Study for Efficacy of Adalimumab Conbined Elemental Diet Therapy for Crohn's DiseaseThe Study for Efficacy of Adalimumab Conbined Elemental Diet Therapy for Crohn's Disease - The Efficacy of Adalimumab Crohn's Disease patient who was ineffective for present therapy and who has not been treated with anti TNF alpha antibody.1)Adalimumab (HUMIRA 40mg for SC Injection)

Inject SC 160mg on Day 1, then inject SC 80 mg on Day 15, and inject SC 40 mg every other week, beginning on Day 29.

2)Elental(1 kcal/ml; 80g/300ml)
Kenji WatanabeNULLComplete: follow-up completeNot applicableNot applicableMale and Female40Not selectedJapan
4NCT01661257
(ClinicalTrials.gov)
October 20097/8/2012Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-a TherapyExpression of T-cell Immunoglobulin- and Mucin-domain-containing Molecule 3 (TIM-3)and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-a TherapyCrohn's DiseaseDrug: InfliximabSamsung Medical CenterNULLCompleted13 Years17 YearsBoth20Phase 3Korea, Republic of
5EUCTR2007-002716-26-IT
(EUCTR)
04/03/200812/02/2008A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn?s disease who have participated in study C87085 - NDA phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn?s disease who have participated in study C87085 - ND Crohn?s disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Product Name: certolizumab pegol
Product Code: CDP870
INN or Proposed INN: certolizumab pegol
UCB CelltechNULLNot RecruitingFemale: yes
Male: yes
200Phase 3Hungary;Finland;Czech Republic;Belgium;Estonia;Italy;Latvia;Austria
6EUCTR2007-003239-21-FR
(EUCTR)
05/02/200815/01/2008A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when treatment is administered in two different settings : either at hospital or at home - PERFECTA phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when treatment is administered in two different settings : either at hospital or at home - PERFECT Crohn's disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Product Name: Certolizumab pegol
Product Code: CDP870
INN or Proposed INN: Certolizumab pegol (rINN)
Other descriptive name: Anti TNF humanized antibody Fab fragment-PEG conjugate
UCB PHARMA S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 3France
7EUCTR2007-002716-26-BE
(EUCTR)
22/01/200816/10/2007Clinical study to assess the long term safety of certolizumab pegol,administered at weeks 0, 2 and 4 and every 4 weeks thereafter, inpatients with Crohn's disease and who participated in a previous studyencoded C87085A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn’s disease who have participated in study C87085. Crohn's disease
MedDRA version: 16.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: certolizumab pegol
Product Code: CDP870
INN or Proposed INN: certolizumab pegol
Product Name: certolizumab pegol
Product Code: CDP870
INN or Proposed INN: certolizumab pegol
UCB CelltechNULLNot RecruitingFemale: yes
Male: yes
500Phase 3United States;Estonia;Finland;Ukraine;Austria;Israel;Russian Federation;Chile;Italy;Hungary;Czech Republic;Canada;Belgium;Poland;Brazil;Romania;Australia;Latvia;Germany;New Zealand
8EUCTR2007-002716-26-HU
(EUCTR)
18/12/200731/10/2007Clinical study to assess the long term safety of certolizumab pegol,administered at weeks 0, 2 and 4 and every 4 weeks thereafter, inpatients with Crohn's disease and who participated in a previous studyencoded C87085A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn’s disease who have participated in study C87085. Crohn's disease
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: certolizumab pegol
Product Code: CDP870
INN or Proposed INN: certolizumab pegol
Product Name: certolizumab pegol
Product Code: CDP870
INN or Proposed INN: certolizumab pegol
UCB CelltechNULLNot RecruitingFemale: yes
Male: yes
500Phase 3Australia;Latvia;Germany;New Zealand;United States;Estonia;Finland;Ukraine;Austria;Israel;Russian Federation;Chile;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Romania
9NCT00606346
(ClinicalTrials.gov)
May 31, 200721/1/2008A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel DiseaseA Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel DiseaseCrohn's Disease;Ulcerative Colitis;Indeterminate Colitis;Inflammatory Bowel DiseasesBiological: Anti TNF therapy including infliximab;Drug: No BiologicsJanssen Biotech, Inc.NULLActive, not recruiting1 Month17 YearsAll4970United States;Canada
10NCT00195715
(ClinicalTrials.gov)
September 200413/9/2005Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's DiseaseA Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's DiseaseCrohn's DiseaseBiological: AdalimumabAbbottNULLCompleted18 Years75 YearsAll777Phase 3United States;Australia;Belgium;Canada;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom